Lisenid

1 known investors

LisenID develops a molecular diagnostics test and AI-driven platform that uses Loss of Imprinting biomarkers to identify carcinogenesis and predict cancer in routine tumor biopsy samples. The platform serves clinicians and patients seeking clarity on ambiguous tumor biopsy results across multiple cancer types including lung, thyroid, cervical, and others.

AI & Machine LearningBiotechMedical Devices